A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation study of the study drug YH003 . The study is designed
to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2
dose (RP2D) of YH003 in subjects with advanced solid tumors.